After a record-breaking 2019, here are the key value-creation issues to look out for in the new decade
There are significant gains for branded pharma in the agreement. But in several other areas, China has made commitments it already meets
The award of $448 million in antitrust damages against the company in case brought by the Federal Trade Commission is also at stake.
Oral hearings before the EPO’s Boards of Appeal may have a big impact on the European Cas9 landscape
Decision not to hear Athena dispute will disappoint many, but may prove catalyst to reinvigorate stalled efforts to reform US patent eligibility regime
Apple top defendant again; Eastern District of Texas loses further ground; and other key stats
Medtech leader Masimo accuses tech giant of patent infringement and trade secret theft
Move by Parallax Health Sciences is an indication that patent assertion plays could increasingly affect life sciences companies as their use of digital technologies increases
Last year patent agencies came under scrutiny for gaming the system, and corporate IP managers say they expect tighter auditing in the year to come
Search giant claims Fed Circuit ruling threatens interconnected software ecosystem, while three 101 cases also on Supreme Court’s radar in big term for rights owners
A precedential decision last month makes it easier for rights holders to assert successfully against imported products
Impending US-China deal, a big Supreme Court ruling in India and a new licensing programme from Toyota are among the regional highlights
The California case was one of the early patent battles over the breakthrough cancer cell therapy technology, which is set to become a crowded space in years to come.
Arlington-based firm acts for more of the companies that own the biggest US portfolios than any other, with Foley & Lardner and Harness Dickey & Pierce rounding out the top three
In an exclusive interview, Adam Stoten, the of COO Oxford University Innovation - one of Europe’s largest tech transfer offices - explains the challenges of protecting and commercialising early-stage life sciences inventions